Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is a pharmacokinetics (PK) and safety study of AZD7295 in healthy volunteers.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| AZD7295 | Experimental |
| |
| Matched placebo | Placebo Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| AZD7295 | Drug | Up to 650mg AZD7295 capsules per dose. To be given 2 or 3 times daily for 5 days. |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Pharmacokinetics of AZD7295 capsules | PK parameters of AZD7295 will be measured after single and repeated doses (AUC, Cmax, t1/2) | 0-72h after each dose |
| Measure | Description | Time Frame |
|---|---|---|
| Safety and tolerability of AZD7295 capsules | Safety and tolerability of AZD7295 will be assessed after single and repeated doses (adverse events, ECGs, vital signs, safety laboratory tests) | 0-72h after each dose |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Jo Collier, Mb ChB | Quotient Clinical Research | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Quotient Clinical Research | Nottingham | United Kingdom |
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo comparator |
| Drug |
Placebo capsules |
|